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Dear Editor, Erythemal episodes during phototherapy can be painful, limit efficacy due to premature 
discontinuation of treatment and may contribute to chronic cutaneous damage. Many patients 
receiving phototherapy take photosensitive medications. Stern et al., investigated 1,125 patients 
receiving maintenance psoralen-ultraviolet A photochemotherapy (PUVA) for psoriasis and did not 
detect a significant difference in risk of erythemal episodes between those receiving 
photosensitising medication compared with those who were not1. However, amongst older (45 
years-old) users of photoactive drugs, 10% discontinued PUVA for at least a month because of 
“burns” compared with only 5% on “non-users”. 
In Tayside, a study of 401 patients receiving narrowband ultraviolet B phototherapy (NBUVB) 
revealed that some photosensitising medications, particularly calcium channel antagonists, 
phenothiazines and non-steroidal anti-inflammatories (NSAIDs), were associated with a lower 
baseline minimal erythema dose (MED)2.   
In this current retrospective cohort study, we investigated whether patients taking photosensitising 
drugs were more at risk of developing significant erythemal episodes during NB-UVB phototherapy 
than those who were not. 
All patients receiving NB-UVB phototherapy to at least photo-exposed sites between January 2012 
and December 2015 in the Dundee phototherapy unit were studied. Caldicott Guardian Approval 
was obtained. Exclusion criteria included patients receiving phototherapy for photodermatoses or 
vitiligo and those who received <10 or >200 sessions. Patients with erythema not formally graded 
(mainly those receiving home NB-UVB) and those with an ambiguous medication history were 
excluded. Erythemal episodes were included if they were at least grade 2 (well-demarcated and 
uncomfortable). Grade 3 erythema was defined like grade 2 but definitely painful and grade 4 as 
severe with blisters. Erythema considered to be from outdoor exposure was discounted. This 
information was obtained from Photosys, the database of the National Managed Clinical Network for 
Phototherapy in Scotland and the patients’ phototherapy notes. 
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Potentially UVB photosensitising medication groups evaluated were NSAIDs, thiazide and loop 
diuretics, retinoids, sulfonylureas, phenothiazines, H2 antagonists, calcium channel antagonists, 
tricyclic antidepressants, tetracyclines and quinine. 
There were 1067 NBUVB phototherapy courses, in 880 patients, fitting the above criteria. Most (702) 
were single patient courses, but 365 were repeated courses in individual patients (maximum 4 
courses). Mean age was 46 (range 6-90) years and 50.2% of courses were for females.  Skin 
phototype II predominated (53.4% of courses), with skin phototype VI being the least frequent (0.1% 
of courses). Psoriasis was the most common indication for phototherapy (54.6% of courses). 
The median number of treatments per course was 28 (range 10 to 98). The median MED was 
0.139J/cm2 (range 0.025-3.53J/cm2) with no detectable difference between MED for the 
photosensitising drug group and the control group. 
Of the 56 grade 3 and 4 reactions, 53.6% were localised. The face was the most common site, 
accounting for 30% of localised cases. 
There were 276 courses during which patients taking potentially photosensitising medication 
(25.9%) and 42% of this group experienced an erythemal episode of grade 2, compared with 36% of 
controls, that is 6% more (95% confidence interval 0% to 13%; p=0.06) (Figure 1). 
Patients receiving photosensitising medication were also more likely to have an erythemal episode 
of grade 3 (7.2%) than controls (3.2%), that is 4% more (95% confidence interval for difference 1% to 
7%; p=0.0053) had severe erythemal episodes in the photosensitising drug group (Figure 1).  
There was a total of only 4 grade 4 episodes in all courses, demonstrating that grade 4 erythema is a 
rare event whether on or off photosensitising drugs. 
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Patients receiving UVB courses and concomitant quinine ingestion were most likely to develop an 
erythemal episode of grade 2 or above (83.3% of those on quinine [n=6]), followed by those taking 
tetracyclines (68.8% of those on tetracyclines [n=16 ]) and tricyclinc antidepressants (62.1% of those 
on these drugs [n=37]).  
There was no detectable difference between number of erythemal episodes recorded and the 
number of classes of photosensitising medication a patient was taking. 
This study suggests that, despite using starting doses based on an individual’s NB-UVB MED, patients 
taking photosensitising medication were still more likely to develop important (grade 2 or more) 
erythemal episodes during NB-UVB phototherapy. It is therefore essential that a detailed drug 
history is taken prior to commencement of phototherapy, in addition to establishing a baseline MED 
and that any medication changes during treatment are highlighted.   Although these medications 
were associated with more important erythemas, the proportion who developed severe erythema 
was low. It is important that patients are not deprived of the opportunity of phototherapy because 
of their medication, although potentially photosensitising medication should be stopped whilst a 
patient is undergoing phototherapy when possible. Patients should be counselled about this 
increased risk of erythema with photosensitising drugs during phototherapy and should be 
encouraged to report medication changes. While the dosing incremental change remains the same 
as those not on photosensitive medication, it could be adjusted for those on photosensitizing 
medication experiencing erythemal reactions. 
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Figure 1: Percentage of courses associated with erythemal episodes in those receiving 
photosensitising medication       and in the control patient group  
 
0 
5 
10 
15 
20 
25 
30 
35 
40 
45 
50 
Grade 2 Grade 3 Grade 4 
Pe
rc
e
n
ta
ge
 o
f 
p
at
ie
n
ts
 (
%
) 
Erythemal grades subdivided by those on photosensitive medication and 
those not 
No Yes (*)   p = 0.06    (**) p =  0.0053 
*
**
